Table 2.
Recipient | Donor | Paired recipient | ||||
---|---|---|---|---|---|---|
|
|
|
||||
HCV RNA IU/mL | HCV Ab | Genotype | HCV RNA IU/mL | |||
Week 12 ot * | Week 12 fu # | Week 4 ot * | Week 2 ot * | 3a | 583 | 1 |
|
|
|
||||
0 | 0 | 0 | 0.37/0.11 | 1b | 369000 | 2 |
|
|
|
||||
0 | 0 | 0 | 0.04/0.2 | 2a | 727000 | 3 |
|
|
|
||||
0 | 0 | 0 | 0.06/0.04 | 1b | 168000 | 4 |
|
|
|
||||
0 | 0 | 0 | 2.07/1.68 | 3b | 147000 | 5 |
|
|
|
||||
0 | 0 | 0 | 1.72/1.29 | 3a | 654000 | 6 |
| ||||||
0 | 0 | 0 | 0.11 | |||
|
|
|
||||
0 | 0 | 0 | 0.02 | 2a | 342000 | 7 |
|
|
|
||||
0 | 0 | 0 | 0.08/0.09 | 3b | 113000 | 8 |
|
|
|
||||
0 | 0 | 0 | 0.05 | 1b | 217000 | 9 |
|
|
|
||||
0 | 0 | 0 | 0.04/0.07 | 3a | 668000 | 10 |
|
|
|
||||
0 | 0 | 0 | 0.42 | 2a | 438000 | 11 |
|
|
|
||||
0 | 0 | 0 | 0.09/0.08 | 3a | 935000 | 12 |
|
|
|
||||
0 | 0 | 0 | 0.03/0.07 | 3b | 477000 | 13 |
|
|
|
||||
0 | 0 | 0 | 0.2/0.08 | 1b | 537000 | 14 |
|
|
|
||||
0 | 0 | 0 | 0.08/0.05 | 3b | 1100000 | 15 |
ot – on treatment of antiviral therapy;
fu – follow-up after antiviral treatment.